Digital health innovations
We are actively seeking proven digital innovations that improve the health of people in the region and raise the quality, efficiency, safety and cost-effectiveness of delivering healthcare.
We are particularly interested to hear about innovations in the following categories:
  • Health maintenance - supporting people in maintaining their physical and mental wellbeing,
  • Prevention - alerting patients, carers or professionals when there are signs that things aren’t going well, and an intervention can prevent crises or emergencies
  • Access - providing more convenient and cost-effective ways for patients and professionals to interact. (e.g. remote monitoring or virtual consultations).
  • Learning and education - delivering information and knowledge to patients about their health or condition, or to professionals to support their continuous professional development
  • Pathways - providing tailored information to patients, carers and professionals on services to signpost people to the most appropriate place.  Ideally, this could be enhanced with real-time information about capacity.
  • Research - using digital tools to promote involvement in research & clinical trials, to streamline the capture of informed consent, and to capture research data more efficiently and conveniently.
  • Integration - tools that enable the secure, appropriate sharing of information between organisations (e.g. GPs and hospital clinicians) and sectors (e.g. NHS and Social Services) to allow patients to receive seamless care.
  • Data Visualisation - innovative ways of presenting information in a meaningful way to enable more informed decisions by patients and professionals.  This may involve aggregating data from different sources, reporting tools or graphic visualisations such as heat maps.

Ideas (Long term conditions: a whole system, person-centred approach)

Innovation 'Elevator Pitch':
MyDiabetesMyWay is a proven, scalable, cost-saving self-management platform/app empowering people with diabetes to take ownership of their disease, data and treatment; delivering tailored support from NHS health record/ home recorded data.
Overview of Innovation:
MyDiabetesMyWay (MDMW) has been running since 2008 in NHS Scotland ,and is now being implemented in NHS England (e.g. Somerset, Manchester, NW London). MDMW is a cost saving (ROI>4:1) online web-based platform with over 50,000 registrants (covering all types of diabetes) funded by NHS/ government, giving patients access to their institutional (NHS) health records, integrating with home-recorded data, utilising algorithms and data linkage to drive highly tailored self-management advice and reports, communications tools and education resources.

MDMW has peer reviewed published evaluation and is an international exemplar having won many quality awards e.g. European ehealth adopters award (2017)/ Diabetes UK self-management award (2015)/ UK Quality in Diabetes Care award (2013). MDMW impacts on clinical outcomes e.g.HbA1C, is low cost (£1-2 per population patient per year license) and offers savings through reductions in complications/ efficiencies in care for NHS providers, and can be rapidly scaled across regions and countries.

THE PRODUCT:
MDMW is a portal/app encompassing:
  • >200 digital educational resources (text, video, interactive content)
  • Patient electronic health record access (institutional NHS data)
  • Patient self-management decision support with data-driven tailored advice/web links
  • 6 QISMET accredited structured education courses (GDM, Type 1, Type 2)
  • Personalised care planning documents
  • Personalised care quality reporting (e.g. DUK 15 Care Measures)
  • Patient goal-setting tools
  • Communication tools; secure messaging with health care team/ peer discussion groups
  • Remote glucose monitoring support (community upload and sharing of home blood glucose (sugar) readings and feedback).
  • External social media channels
  • Responsive and accessible web/mobile platform design
"Patient access to diabetes records through My Diabetes My Way has meant a step change in the care and understanding of my condition to a level that it has never been. I am much more in control of my condition but importantly I now understand the goals that I should be achieving and am able to have a constructive discussion with my consultant. "

MyDiabetesMyWay is now being rolled out in sites across NHS England.

MyDiabetes Clinical is a complementary clinician facing platform delivering a EHR, automated clincian guidance driven support, and individual and population analytics

http://www.mywaydigitalhealth.co.uk/
E: david.garrell@mwdh.co.uk
M: 07739 529737
E: debbie.wake@mywaydigitalhealth.co.uk
M: 07904154101
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Digital health
Benefit to NHS:
MyDiabetesMyWay is a novel patient facing intervention which can directly impact on clinical outcomes, quality of life, and improve efficiencies in service delivery. Diabetes is growing health problem with high treatment costs affecting 9.6% of the WM population. Good patient self-management driven by education, empowerment and motivation is key to good outcomes. Diabetes spending may rise over 10 years to c. 17% of the NHS budget.

People with diabetes only spend a few hours per year with health care professionals. The rest of the time, patients self-manage their condition; i.e. - blood glucose monitoring, medication adjustment, appropriate daily foot care, weight management and dietary and activity choices. Self-management is key to reducing costly long-term complications such as ulcers, amputations, blindness, kidney disease, heart disease, stroke/ vascular disease, mental health disorders, sexual dysfunction and neurological complications.

MyDiabetesMyWay delivers cost savings and better outcomes for patients (ref: published evidence), it also improves data transparency for practitioners across primary and secondary care and can reduce the need for face to face education and consultation, improving efficiency in working practices. Regular knowledge updates, feedback on results, motivational support and flexible access to health care staff are key to supporting patients, reducing costly clinic visits, hospitalisations and death due to secondary complications, leading to longer healthier lives with significantly reduced costs.

Technology approaches in diabetes care work well, particularly if they are personalised. Low cost population based solutions are appealing in the current climate of rising prevalence on a shrinking NHS budget. Long-term conditions management needs to evolve to reap the potential benefits of data driven approaches. There is massive potential for wider lifestyle/home monitoring/institutional big data analytics to drive push notifications and automated decision support in real time to patients, which could transform care delivery. Our product development supports this evolution.

MDMW can contribute to the local implementation of the NHS Long Term Plan. EG:

3.81 supporting delivery across primary care to enable more to achieve treatment targets
5.9 & 5.13 People seamlessly empowered by digital tools information and services/digital structured education.

Demonstrable through Tests 2/3/4 (£ releasing/reduce demand for care/reduce of unwarrant)

 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Diabetes is growing health problem with high treatment costs affecting 9.6% of the WM population over the age of 16. Good patient self-management driven by flexible access to good quality information (available in a range of languages), structured education courses, empowerment and motivation is key to good outcomes. MDMW supports achievement of local 3 treatment (BP, cholesterol and HbA1C) and structured education targets.

People with diabetes (PWD) only spend a few hours per year with health care professionals. The rest of the time, patients self-manage their condition; includes blood glucose (sugar) monitoring, medication adjustment, appropriate daily foot care, weight management and correct dietary and activity choices. Self-management is key to reducing costly long-term complications such as ulcers, amputations, blindness, kidney disease, heart disease, stroke/vascular disease, mental health disorders, sexual dysfunction and neurological complications.

MDMW delivers cost savings and better outcomes for patients and improves data transparency for practitioners across primary and secondary care and can reduce the need for face to face education and consultation, improving efficiency in working practices. This combination of empowered PWD and practitioners with a more complete picture can lead to more frequent co-production of health with the patient at the heart of decision making.

Digital Health Innovations - MDMW can deliver in the following categories: 
  • Health Maintenance – MDMW is a patient support platform for those with diabetes and the combination of data linkage/their own data and information/structured education enhances motivation to self-manage.
  • Access – by accessing their records and data remotely patients can choose to access health care, we have a clinical system just starting to deploy which can further enhance this.
  • Pathways – as we build (in collaboration with the local diabetes services) a website containing all local services and which acts as the access point to all the assets in MDMW we act as a signpost to patients (we do not provide real time capacity information at this point).
  • Integration/data visualisation - this is a strength of My Way Digital Health – we specialise in data integration and provide this to patients and health care professionals in different ways. The patient visualisations are particularly powerful and helpful. E.g. 90% of patients report an improvement in the quality of their consultations as a result of using MDMW.
Current and planned activity: 
MDMW is currently deployed throughout NHS Scotland. MyWay Digital Health are now implemented/ing MDMW in sites in NHS England, including Somerset, NW London and Greater Manchester. We were selected as one of 11 NHS innovation accelerator programme fellows (2018 cohort) and the Digital Health London accelerator, both of which are supporting adoption.

We continue to develop the product including Artificial intelligence/machine learning, decision support and a corresponding clinician platform through Innovation funding.

This will further enable delivery of the long Term Plan and section 5.29:

"Decision support and AI ... technologies need to be embraced by the NHS, but also subjected to the same scrutiny that we would apply to any other medical technology. In the coming years AI will make it possible for many tasks to be automated, quality to increase and staff to focus on the complexity of human interactions that technology will never master.
See files for company skill profile.
What is the intellectual property status of your innovation?:
Intellectual Property for MDMW is fully assigned to the company from the University of Dundee for exploitation.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Regional Scalability:
Implemented at scale across NHS Scotland since 2008 (currently> 35,000 registrants), Implementing in Somerset CCG and across NW London STP. Working on applications in Greater Manchester and other areas.
Measures:
Previous Assessment in NHS Scotland:

MDMW clinical impact has been assessed (April 2017) using time-series analysis comparing HbA1c of active users with those in the inactive background patient population (control cohort) matched by age, duration of diabetes, socioeconomic status and gender (7147 interventions (registrants and active users) vs 36020 matched subjects). My Diabetes My Way (MDMW) users demonstrated a sustained 4 mmol/mol HbA1C reduction. Further health economic analysis based on UKPDS complications models and £1 per diabetes population annual charge/ 5-10% registration, suggests a return on investment of around 6:1. User surveys; 90% feel MDMW supports diabetes knowledge, self-management and motivation.

Ongoing Assessment:

- Identifying strategies/ barriers for successful implementation and uptake.
- Gather feedback on new product feature to assist in ongoing product development
- Assess changes in health outcomes, complications prevention and health economic benefits 
- Assess changes in working practices/ care delivery efficiencies e.g. impact on consultation numbers, face to face education, unnecessary screening tests

*Outcomes will be added to the health economic model
Adoption target:
We would aim to offer to everyone in the region with diabetes and rapidly onboard 5-10% of the entire diabetes population in your area in the first 12 months. Our intervention USP is low cost and scalability (at no additional per person cost).
Read more
Hide details
David Garrell 18/09/2019 - 14:58 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Caburn Health integrates IoT technology solutions for health and social care to enable patients with long term conditions to stay safe and well in their own homes.
Overview of Innovation:
Caburn Health develop and deploy technology solutions for integrated health and social care provision, answering the challenges set by aging populations and ever more thinly stretched budgets.

Our Home Hub allows simple connection of authenticated health, social care and home automation devices using open industry short range wireless standards to create a single view of the patient’s wellbeing, the environment around them and how they are interacting.

Scalable and future-proof
Our major focus is in delivering simple to use, stand-alone, highly extensible monitoring and reporting systems based on open industry standards to ensure future relevance and interoperability with existing technologies.

Security
The secure data platform can be easily configured to direct monitored data, alerts and alarms to the relevant people and systems by any preferred method or protocol.

The benefits are enjoyed by:

Patients, who spend the maximum time in familiar surroundings, minimise or avoid acute illnesses and exposure to the risk of hospital acquired infection.
Health Services, who reduce the number of emergency admissions to over-full hospitals, and are enabled to discharge recovering patients to home more quickly freeing beds for new arrivals.
Families of patients, who are better able to monitor the care and wellbeing of their relatives with less disruption to their daily lives.

Our partners include:

Atos, who provide scale capability, logistic and systems integration support.
M2M Intelligence, who provide resilient, managed multinetwork SIMs and data services.

 
 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Digital health
Benefit to NHS:
The Caburn Health solution enables clinicians to remotely read sensors placed in the patient's home, thus reducing the need for home visits, enabling community healthcare teams to manage a greater workload and with increased efficiency.
Long terms conditions can be more closely monitored and the instances of acute episodes and unplanned hospital admissions can be reduced.

Acute hospitals can further benefit by being able to discharge patients to home with more comprehensive care package in place for close monitoring during transfer of care to the community team.
Patients benefit by remaining at home for longer and maintaining stability in the management of their condition(s).
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
The local West Midlands population is aging, and incidence of Long Term Conditions ('LTCs') are increasing in line with the national trends, the Caburn Health solution can help to reduce the cost burden to local budgets of unplanned admissions to acute hospitals, can reduce 'bed-blocking' or delayed transfers of care. The local population will also directly enjoy the benefits of remaining safe and well at home for longer and reduced incidences of acute illness when managing LTCs.
Current and planned activity: 
A trial is underway with the NHS in Scotland, on the Western Isles, in conjunction with Atos Consulting UK which is running in parallel with curent practice to establish a baseline and to prove the technology. A full analysis of the results will be available at the end of the trial (late 2019 / early 2020). During 2019 / 20 further trials are in planning stages for across the UK, and EU.

In addition to trials with NHS Western Isles focused on long term physical health conditions, Caburn Health is also working with research teams from Sheffield and Oxford Universities to evaluate the use of IoT technology in the management of Mental Health conditions. This is at an early stage of defining requirements and scoping the structure for the investigations.
 
What is the intellectual property status of your innovation?:
Caburn health have built a device management platform (copyrighted code) that enables the operator to monitor the connected state of each Hub and to verify any peripherals attached to it. Parameters such as battery life, connectivity (3G / 4G), sensor calibration status etc. are reported back to the platform in near real-time.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Matthew Owen 22/07/2019 - 10:38 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Amplitude pro enterprise™ uses simple technology to capture clinical and outcome data for specific diseases, diagnosis, interventions and care pathways. Data is retained locally and available for immediate reporting and analysis.
Overview of Innovation:
The Amplitude pro enterprise™ software is a simple, tailored online platform centred around two crucial elements:
A user-friendly electronic patient portal which gives patients the freedom of completing their scores online at home, on site and via various devices and a consultant dashboard giving the clinician(s) the ability to input patient specific complexity factors and procedure data quickly and easily.

The result is representative, accurate and meaningful data that paints a clearer picture of each patient’s level of health and expected recovery. Clinicians are engaged with the clinical outcomes processes at your hospital, you get the insight required to innovate your clinical services and patients get a consistently high standard of care.

pro enterprise™ is simple, cost effective and delivers precise and accurate data, selecting scores that are identified as important to you.

The data you collect in pro enterprise™ will allow you to monitor your service delivery, identify quality issues and demonstrate levels of care. Your hospital can be confidently transparent about its activities, resulting in reassurance to your peers that you are offering the best care possible.

Amplitude specialises in the collection of electronic PROMs and clinical outcomes and we are the leading supplier of electronic PROMs to the NHS. We are accredited by NHS Digital for the electronic capture and upload of National PROMs and our platforms have achieved the highest levels of IG compliance, using data centres that are ISO27001 certified. 

Amplitude's unique data exchange tool means that you enter and retain your data locally in your pro enterprise™ platform and the necessary data for clinical registries, National PROMs and NJR can be  pushed to the relevant databases on your behalf.

Our systems are designed to empower clinicians in adding value to their data e.g. proper case mix adjustment, log-book, revalidation report and easy analysis and self-monitoring tools. The system automates the process of data collection via a series of reminders sent to patients via email and SMS. These reminders are triggered from the intervention data which at minimum includes procedure/intervention description and diagnosis. 

Amplitude pro enterprise™ is customised and tailored to suit specific department requirements and objectives including virtual clinics, clinical outcomes and PROMs. pro enterprise™ is currently being used in T&O, Rheumatology, Urology, Cardiology and Mental Health departments.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
The Amplitude pro enterprise™ system captures and manages clinical and PROM’s outcome data with the key focus to improve overall quality of patient care.
NHS healthcare professionals are required in many specialist areas, to monitor the long-term effects of treatments.  Historically, these were captured on a macro level and this mass gathering of non-specific data, results in outcomes data that is non-meaningful and without sufficient detail or context, preventing its use in making effective, informed clinical and management decisions.
In addition, due to the paper-based nature of how PROM’s and clinical outcomes were historically gathered, often, data would only be made available months after being gathered and in an aggregated and anonymised format, rendering it out of date and of little value.

With Amplitude pro enterprise™, The NHS benefits from the ability to;
  • Capture the clinical outcomes of patients in larger numbers and in an electronic format,
  • Effectively measure the quality of care provided by clinicians in real-time
  • Measure the efficacy of the treatments being used on a local, national and international level
  • Reduce costs associated with carrying out the required questionnaires in a paper format
  • Use the data gathered to compare treatment plans and ensure that patients are receiving the best possible care available
  • Increase clinical and patient compliance and engagement in outcome data collection
  • Meet the challenge to make the NHS paperless
  • Opportunity to provide multiple language options; allowing the patient to complete their electronic questionnaires in their native language instantly
  • Use Amplitude's unique data exchange tool to automatically upload required registry data when the information is gathered in the Amplitude pro registry™ platforms, thus reducing administration, duplication of effort and importantly, retains the outcomes data at the source pro enterprise™ system, allowing instant insight
  • Access to comprehensive reporting tools, that include templated validation reports for individual clinicians, further reducing resource, time and effort
Amplitude pro enterprise™ provides the NHS with a paperless, streamlined data gathering software, that reduces costs, has real-time results, meaningful insights for clinical and managerial decision makers and ultimately improves the overall quality of patient care.
Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
The West Midlands AHSN covers 6 regions within the NHS; Birmingham and Solihull, The Black Country, Coventry and Warwickshire, Herefordshire and Worcestershire, Shropshire and Staffordshire.

Within this area, there are 33 NHS Trusts servicing the needs of a population of approximately 7.225 million (ONS 2017). According to the ONS, 18.2% of the population were aged 65 years and over.
It is also documented that over half (54%) of older people have at least two chronic conditions increasing to 69% among those aged 85+ (Kingston, et al., 2018).
Multi-morbidity increases the likelihood of hospital admission, length of stay and likelihood of readmission, raises healthcare costs, reduces quality of life, and  increases dependency. (Kingston et al., 2018).

These are all operational factors being faced in the West Midlands region and the implementation of innovative technologies, to help manage the growing dependency on the NHS, are essential.
The implementation of Amplitude pro enterprise™ will not only allow for monitoring outcomes, it can also use the outcomes data to manage workloads, triage clinics and help to influence operational management. 

Eg; fracture clinics see all patients admitted to A&E with musculoskeletal problems, the system could reduce the number of follow up appointments in Trauma and Orthopaedics clinics by assessing cases in a virtual clinic, prioritising the appointments of patients that require surgery or a clinic appointment and booking those that are less urgent into follow up clinics.

Or: The Amplitude pro enterprise™ platform can provide the method of prioritising more urgent cases in Rheumatology or Cardiology clinics, allowing urgent cases to be seen ahead of patients who are performing well with their current ongoing treatment plan.

Managing the patients according to need and not by pre-set time frames, could help to prevent potential A&E visits by patients who deteriorate or do not respond as expected to their treatment plans.

Administrative workloads can be reduced, and the overall quality of care provided to patients can be dramatically improved, whilst overall cost savings are obtained as a result.

In addition, administrative productivity can be increased with the data exchange tool. For mandated registry data submission such as National PROMs, NJR and now BSR (Apr 2019), data is entered just once and the Amplitude pro enterprise™ platform uploads the relevant information as required, with the data being retained for local analysis.
Current and planned activity: 
With a wealth of NHS experience in the Amplitude team, the products we design and develop have NHS priorities and needs at the heart. When the pro enterprise™ platform is deployed into a hospital or trust, the Amplitude development team continue to improve the system to best service it’s users. Upgrades are released annually, upgrading the functionality on a regular basis.

CCG’s are looking at commissioning based on outcomes and lucrative contracts are sent to the trusts and hospitals with the best results. pro enterprise™ ensures boards can evidence their results to win these contracts, adding funding to budgets.

pro enterprise ™ promotes interoperability. The ability to receive data via exchange from a growing number of PAS’s is a major factor in reducing administrative workload and costs, but when this technology is combined with the ability to also push the data (electronically) to populate the associated registries too, the benefits and cost reductions are multiplied.
What is the intellectual property status of your innovation?:
Amplitude Clinical Outcomes own the intellectual property rights on this platform.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Sarah Steptoe 16/04/2019 - 10:58 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Hospify is a health data platform built on free & trusted messaging for patients and clinicians. A free messaging app is available to all users; a team messaging platform is sold to hospitals, surgeries, pharmacos and other healthcare institutions.
Overview of Innovation:
  • Hospify is an ubiquitous health comms ecosystem that puts patients & clinicians in control of their health interactions in a way that everyone can access and trust
  • Hospify allows patients to connect with and control their communications with healthcare providers, pharmacists, pharmacos and insurers
  • Like Slack in the commercial sector, Hospify uses open standards to enables other health apps and digital services to function within an ecosystem that benefits all parties involved
  • Hospify’s unique “serverless” phone- powered network architecture allows it to scale users without scaling costs while staying compliant with all data regulations.
     
There are lots of healthcare messaging companies popping up. So what makes Hospify different?

1) A messaging platform is only useful if everyone can be on it. That’s why people love WhatsApp. For everyone to be on it, the core platform has to be free. Hospify is built on a unique serverless architecture that allows it to scale the app without scaling the costs of supporting it.  This allows Hospify to offer its core messaging, for free, to everyone, forever, without needing to monetize our users’ data or sell them ads in order to do it. 
2) That serverless structure means that we don’t store users’ data (one of the reasons that we can’t monetize it!). All the data, at least in the free, secure and compliant app, is kept on the user’s device, and only on the user’s device. This means that compliance is baked in from the start, and enormously reduces data liabilities and security overheads - which in turn helps support our ability to provide the app for free to the majority of users.
3) Hospify is really simple to use. Most of our competitors are building complicated messaging tools designed to appeal to doctors. But at Hospify our focus is on nurses and patients - the people at the sharp end of health, who want solutions that are simple and effective and don’t require a manual in order to them figure out.
4) The Hospify messaging app is only part of what we do. Hospify’s secret weapon is the HospifyHub. The Hub transforms the App’s “WhatsApp”- style experience into something that’s more like Slack, with a web portal and a desktop app that syncs with users’ phones without compromising our compliant and scalable “serverless” architecture. The Hub offers administrated groups, broadcast messaging, and data capture via messaging surveys, and is designed to integrate with and handle data from third-party apps.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Efficiency gains from simple, non-siloed comms
Reduced risk of data breach and better clinician & patient privacy
Reduced time to decisions
Fewer face-to-face follow-ups
More timely interventions
Improved patient-centric care  
Improved mobile working
Improved interdisciplinary and inter-organisational working
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
Easier access to clinical professionals
Reduced travelling to appointments
More control over personal health data
Reduced risk of health data breach
Less frustrated clinical staff!
Reduced spend at CCG level on SMS
Current and planned activity: 
Traction (App)
  • Hospify’s free messaging app is live in the Apple & Google app stores with more than 4000 sign-ups across 60 hospitals since launch in Feb ’18 and 25% monthly active users.
The Hospify App is secure and compliant for health use across the UK and EU. End users can download the FREE Hospify App via the Apple and Android app stores.  

Live Trials (Hub)
  • Unison Health: paid trial at University Hospitals North Midlands. Intention to scale out nationally to >1k branches and >500k nurses
  • Birmingham Community NHS Trust: free trial
  • Cambridge & Peterborough NHS Trust: free trial
  • Lincolnshire Community NHS Trust: free trial
  • Medway Community NHS Trust: Up to 900 users for 3 months’ free trial
  • Corby NHS Health Centre (Lakeside+): 90 users for 3 months’ free trial The GP Service: telehealth company with national reach
 
 
What is the intellectual property status of your innovation?:
UK trademarks filed; EU, Colombia & US trademarks in process.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Regulatory Approvals:
When designing its message delivery and information security architecture in 2015, Hospify carried out detailed discussions with the Information Commissioner’s Office about the legislative landscape around secure messaging in health. As a result, Hospify combines cutting edge technology and powerful security with careful consideration of UK and EU rules for handling patient information, and has the following accreditations:
  • GDPR & 2018 UK DPA compliant
  • NHS IG Toolkit (2017-2018) & DSPT (2019) (Org code: 8JN92)
  • Crown Commercial Service supplier (GCloud 11)
  • ISO 27001:2017 accreditation (Registration number: 214722)
  • ICO registered (ZA239336)
  • US encryption export registered (SNAP-R ERN R11191)
 
Read more
Hide details
James Flint 11/03/2019 - 14:39 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Xuper Clinic is a unique patient booking and video consultation solution which promotes efficient healthcare. Our end-to-end solution can integrate with any system, including wearable technology and external diagnostic tools.
Overview of Innovation:
Xuper Clinic is a perfect combination of an appointment booking system and a video consultation platform, which has been designed to streamline patient and doctor interaction. It is designed to enhance the communication and collaboration for all parties involved by saving them time and money.
Our solution allows organisations to customise their workflows and narrate what the end product will look like and how it will work for them. It also provides an end-to-end solution within healthcare, where trusts can use the platform to not only book their patient appointments, but also use the same platform to conduct encrypted and highly secure video consultations. It allows the patients to log into their consultation(s) with a onetime use pin, ensuring that the platform remains secure from unwarranted access. Our platform allows the healthcare organisation to define the data they hold, enabling it to remain consistent with the rest of their systems and any protocols in place. As for Xuper, all of the patients data remains anonymous, we simply maintain information on the platforms usage, such as hours in use and healthcare areas it is being used in. It also has the capability to integrate with existing Patient Appointment Systems (PAS) to ensure a seamless process.
Xuper Clinic is also designed to integrate with external diagnostic tools such as digital stethoscopes for further collection of data, continuity of care and feasibility. Most importantly, the platform integrates with market leaders in wearable technology, Fitbit, which allows consultants to track their patients’ sleep, physical activity and calories burnt for health monitoring purposes.
Current software’s which exist in the market for telemedicine, solely provide a platform for video consultation or telemedicine, however, lack a more thorough or end-to-end solution for continuity of care.
Stage of Development:
Ideas stage - Early concept and ideas stage
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
The biggest benefit of Xuper Clinic to the NHS is the amount of time – and therefore money – it will save as it will allow clinicians to join patient consultations remotely. All of Xuper Clinic’s features were designed to maximise Healthcare Professionals’ efficiency and save them as much time as possible.
Xuper Clinic has a waiting room feature that allows patients to wait in a ‘virtual queue’ whilst clinicians are in video consultations. Once the clinician has finished their virtual consultation, they are able to see the queue, see how long patients have been waiting for, and connect to the patient of their choice. 
If a clinician is running late or is unable to make a certain appointment, they can let their patient know and reschedule the appointment, reducing the build-up of back log for the Trust and lowering the number of people in the waiting room.
By transitioning to a virtual platform for consultations or by deploying Xuper Clinic within the NHS, we are/Xuper Clinic is also preventing the spread of various infections to and from patients and reducing the number of Healthcare Associated or Hospital Acquired Infections.
Furthermore, specialists often have to travel a lot to see a number of patients. This is a big waste of time and money when you could have the exact same consultation from your own office or on the move. Xuper Clinic removes the need to travel as you can connect to your patient no matter where you are.
Clinicians can also maximise their efficiency by sharing documentation, such as patient information, securely and easily over the platform.
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
As a patient, the whole process of getting seen by your Doctor or GP is time consuming and can be extremely challenging. Xuper Clinic will allow patients to be seen much quicker because it maximises clinician’s efficiency by allowing them to see a much higher number of patients in a shorter length of time, as compared to face to face consultations. Traffic The time spent in waiting rooms or queues will also be lowered because the clinicians can get to the consultations in a click of a button.
Most people find it difficult to go visit their GP due to personal or work-related circumstance for e.g. they can’t take time off from work or have to look after their kids; Xuper Clinic will allow patients to join their consultations from the comfort of their home, as long as they have a device with an internet connection. 
Being in the comfort of your own home is a very appealing benefit to the population because they will feel safer and more comfortable, therefore allowing the doctors to get more detailed information to diagnose them properly. This also prevents them from getting ill or acquiring infections from other people/patients.
Xuper Clinic also allows the clinic to send timely reminders to their patients; having the ability to send out email or phone reminders means fewer patients will miss their appointment, ensuring that people take charge of their own health and not delay their healthcare needs.
Current and planned activity: 
We work in a number of areas within the NHS, providing UK based, secure, cloud based video meeting spaces in a variety of situations, predominantly multi disciplinary team meetings.  However, the exciting area of growth is in the provision of video enabled one to one consultations, augmented by an optional concierge service to administer the process and the ability to integrate supporting documentation and data from third party sources, e.g. wearable devices. Current projects are focused on provisioning healthcare consultations from non clinical environments, e.g. home.  Note that this extends to both the clinician and the patient, creating a cost effective and efficient service.  Areas of care include, GP consultations, mental health, COPD and diabetes.
What is the intellectual property status of your innovation?:
We are currently working with an outsourced development team who are developing the platform for us; we own 100% of the development and IP rights and have an in-depth agreement in place, arising to and from work done on and in relation to the platform, along with a complete access to the source code.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
2
Rejection Reason:
Person has left the company
Read more
Hide details
Joshua Price 18/02/2019 - 18:36 Rejected Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Detection of acute, chronic and very early stage diseases in real time based on tests results and alerting all authorized parties about detected problems with of the essential patient information on mobiles, tablets and computers.
Overview of Innovation:
As it could be integrated and is constantly receiving data from current lab and EHR systems, it immediately detects problems in lab test results and informs doctors about new lab data received and issues detected for a particular patient. It gives access to historical data with some valuable statistical calculated and visualised data which helps doctors to understand acute, chronic, hidden or early stage health problems over secure web/mobile/tablet applications, so doctors can see these results for making better and correct decisions any time and in any location they are in at any moment.
 
Core applications of the solution are:
1. Speeding up doctors’ workflow in hospitals. At the moment, doctors in NHS have to go to rooms where there are computers with access to lab data. Quite often, doctors spend time waiting for each other to get access to their patient blood test data.

An essential part of the solution is the mobile/tablet application which can be installed on any mobile operation system iOS/Android. Which lead to:
  • Freeing up to 2 hours of doctors’ time daily
  • Increasing patient turnaround time on average by 25%
  • Increasing time reaction on most critical acute cases up to 99% 
2. In Doctors’ practice, there have been cases when a delay in days, hours or minutes in getting lab data in time is crucial for a patient’s life.  

Platform is constantly tracking blood data from the lab system, it analyzes it and alerts about critical changes in lab tests metrics and it immediately sends notifications to related parties to pay attention on a particular case.

At the moment, it tracks more than 25+ diseases and all other blood test parameters and (early and acute): AKI + CKD (all types), Sepsis and much more.

3. Platform provides historical analysis tools for blood results and gives some related insight information for each particular test parameter, so it is quick and easy to see the problem and identify potential problems at a very early stage and apply preventive actions to avoid problems. 

4. Platform has a recommendation system which seeks potential hidden problems in results. If those potential hidden problems are found, the platform gives an explanation and list of additional tests required to confirm potential problems.

5. For management team it provides deep business insight (visulised with over the time progression) of a difference scale: Hospital, Groups of Hospitals and National level about detected problems, about performance of laboratories, doctors and etc.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Potential impact of the Pin.Health on NHS
 
Product results in efficient improvements:
—  Increases time reaction on most critical acute cases up to 99%, that decreases the amount of fatal cases in hospitals
—  It frees up to 25% of doctors and GP’s time daily
—  Increases patient turnaround on average by 25%
—  Saves money on unnecessary blood tests and use of hospital beds

Product results in cost improvements:
—  It saves more than £18,000.00 GBP per doctor per annum
—  Decreases amount of unnecessary admissions up to 25%
—  Increases revenue up to 20% with the same medical headcount for commercial healthcare companies
—  Decreases the amount of unnecessary sales and blood test results in labs
—  Significant healthcare budget decrease on investment in huge IT project
 
Product results in patient care improvements:
—  Increases time reaction on most critical acute cases up to 99% that decreases the amount of fatal cases in hospitals
—  Early stage disease identification with more than 95%+ accuracy rate, and it keeps growing. It prevents serious illness conditions — move focus to preventative medicine
—  Decreases amount of fatal cases at the Hospital
—  Decreases number of doctors’ errors or human factors
 
Pin.Health supports the HSCIC Strategy (NHS Digital) 2015–2020 Strategy as well as some general European Union Strategies in Healthcare.
  1. Ensuring that every citizen’s data is protected
    Platform follows HIPAA, GDPR and UK Law in relation to data access and protection. 
  2. Establishing shared architecture and standards so everyone benefits
    Platform has API based on industry-standard protocol FHIR HL7 (JSON based protocol). Any trusted (pre-authorized by NHS) 3rd party applications and systems can connect to Pin.Health over a secure connection over API and get access to data it has, and results it has produced. 
  3. Implementing services that meet national and local needs
    As platform provides access to data and results it produced over API — any external trusted applications/systems can be built on top of it to solve other problems.
  4. Making better use of health and care information
    Pin.Health solves numerous problems which helps improve workflow in hospitals, speed up process of disease identification to save patients’ lifes and to avoid critical conditions, moving the focus to preventive medicine, proceed researches based on data platform aggregates. All of it implements better use of health and care information.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
In some doctors’ practices, there have been cases when a delay in days, hours, or even minutes in getting lab data in time is crucial to a patient’s life. Our platform solves this such challenges.

The platform is monitoring data from 3 perspectives — first it’s trying to detect acute diseases, after it recognizes chronic conditions and early stage conditions for each newly received test.
 
At the moment, we are tracking more than 25 diseases such as Acute Kidney Injury and Chronic Kidney diseases of all types, Anaemia of all types, Liver Disease and others, as well as all test parameters, whether they are out of range or not, and if they are at a chronic stage or an early stage.
 
One example is the AKI (Acute Kidney Injury) which is one of the diseases that is tracking in our system. AKI is a sudden and recent reduction in a person’s kidney function.  Despite the high incidence, AKI in hospitalized patients is characterized by a high rate of missed diagnosis. The missed diagnosis rate is about 57% even in high-income countries. In the UK, 1 in 5 emergency admissions into the hospital are associated with AKI, with up to 100,000 deaths each year in hospitals associated with acute kidney injury. From official UK NHS statistics, up to 30% could be prevented with the right care.

All in all platform leads to NHS operational, financial improvements as well as in longer and stronger health of the West Midlands population.
Current and planned activity: 
We would be interested in running the pilot project with one of the NHS Trust or Hospital for a period of 2-4 months. Afterwards, integration will be completed. To gather statistic about platform performance and getting first feedback from clinical environment, which leads to futher platform improvements and scaling benefits which platform gives over other NHS Trusts.
What is the intellectual property status of your innovation?:
Company is IP holder of the solution.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Anonymous 05/12/2018 - 00:09 Publish 3 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Kemuri portable K-Sockets have a 500% return on investment in one year. Use them to accelerate hospital discharge of elderly or frail people into reablement by social services.
Overview of Innovation:



Kemuri K-Sockets are power sockets with multiple sensors that continuously measure:
  • Movement of people in the kitchen;
  • Electrical power for kettles, microwaves or toasters;
  • Room temperature;
  • Power supply.
They send data via the Internet via GSM mobile phone communications.  Kemuri software learns patterns of normal activity and analyses Activities of Daily Living (ADLs) every hour.  As soon as the system identifies too many changes from normal, it automatically alerts people who need to respond to possible risks.  Responders can be families, carers or 24/7 alarm response centres.

The WebApp gives evidence of reablement of the service users.  It gives confidence to responders who have been given informed consent to view the data.  For example:
  • Wandering or unattended falls: Kemuri alerts non-return to kitchen;
  • Nutrition & Hydration: Kemuri alerts risk of dehydration or malnutrition;
  • Engaged the Community: Kemuri apps are free to authorised family, carers or voluntary sector;
  • Active in the home: If people can eat, drink and move around in warm surroundings – then they are performing key ADLs.
Portable K-Sockets are allocated to discharge teams as part of the normal hospital discharge process. Families or other carers have to respond to alerts and determine the action to be taken.  The devices are re-allocated to patients every 6 weeks. Thereafter fixed K-Sockets can be installed in kitchens as wellbeing monitors. 



The cost is less than £500 per year, and the notional saving on bed days is approximately £400 per day.  By using a unit eight times per year, more than £3200 budget is released for more patients.  This represents more than 500% return on investment in one year.  This must be worth a trial in the region.  Additional benefit can come from reduced re-admissions.

Surrey County Council have awarded a grant of £50,000 for measuring the reablement process and subsequent wellbeing monitoring.
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Two areas of immediate benefit are the saving of excess bed days for non-medical reasons and the avoidance of re-admission. 
  • Many elderly and frail people cannot be safely discharged from hospital without a period of reablement by family members or professional domiciliary carers.  The NHS typically funds this for a maximum of six weeks – at lower cost than the occupation of a hospital bed.  After assessment and transfer of care to social services, continuous monitoring by K-Sockets permits safe discharges a day or more earlier.  This eases the problems of Bed Managers seeking to release beds for new patients.
  • During reablement, automatic alerts warn of unusual changes of activity.  They could indicate the risk of unattended falls, dehydration, malnutrition of hypothermia; all costly to the NHS.  Appropriate action could avoid the need for re-admission.  
Kemuri is designed for both family carers and 24/7 response services.  Portable K-Sockets require zero installation time and do not require broadband.  Monitoring and machine learning starts within minutes and any people with consent for data sharing can immediately view the data or receive alerts.
 
Longer-term benefits come from wellbeing monitoring after reablement.  Portable K-Sockets can be replaced by fixed K-Sockets.  The data analysis could reveal medical problems, such as UTIs, and preventive action could avoid more costly treatments.    
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
Most older people want to return to their own homes as soon as possible after treatment.  Unfortunately, for some independent people, they cannot be discharged because there is no care provision at home.  Perhaps they have no local family or friends.  Consenting to reablement monitoring by K-Sockets could accelerate their discharge and improve health outcomes. 

Families also obtain peace of mind, whether they live locally or at great distances.  At any time of day, people can be alerted to possible problems and respond appropriately.  Most frequently it may only require a reassuring phone call.  On other occasions it could be an unattended fall or medical event that needs clinical action.  Earlier treatment leads to better health outcomes.

It may be possible to reduce the costs of domiciliary care with more-timely and less frequent visits. 
This is an example screen:


A green day shows normal activity.  An amber day shows more changes from normal activity – but may not be cause for alarm.  Red days are alerted during the day and are a call for action.  Viewers can drill down to more detail, and the screen below could indicate the risk of hypothermia.

K-Sockets are invaluable as passive monitors to supplement active telecare devices, such as pendant alarms.  The latter are not worn continuously by 90% of the people who have them and they need reasonable cognition to use them when necessary.  K-Sockets are not stigmatising and do not require any change of lifestyle.

For more information and downloads see http://www.kemurisense.com


 
Current and planned activity: 
Cornwall Council is trialling 20 portable K-Sockets for reablement.  In one case, an alert was sent to a family member before they knew about an unattended fall.
 
Surrey County Council have awarded a grant for TECS Innovation.  The plan is to supply 40 portable K-Sockets for reablement and then supply 100 fixed K-Socket to vulnerable people for six months.  Social Care will perform assessments as part of their normal case management.  An anonymised log of each service user should provide evidence of the bed days saved.  Statistics of readmission or transfer to full-time residential care can be compared to current averages.
 
Many K-Sockets are operational in small trials and some are still operational after years of use in private houses and housing association properties.  They could collect data for several years in long-term trials for clinical trials, such as for drugs for relieving the symptoms of dementia.
What is the intellectual property status of your innovation?:
Kemuri has patents pending; GB1417259.7, effective date of 30 September 2014 and PCT/GB2015/000275, International Filing Date of 30 September 2015. 
 
Kemuri, KemuriSense, K-Sockets and K-Fobs are registered trademarks. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
K-Sockets can be produced in batches of 100 to 1000 from a factory in Woking.  If demand rises, second sourcing could be obtained in the WM region.
 
Web services are cloud-based and rapidly scaled at short notice.  Surrey has the largest scale implementation, which should peak at 140 units.  Scale-up should start by engaging with hospital discharge units and reablement teams.  Services to self-funders and Local Authorities can be scaled up by using the larger telecare service companies who provide other equipment and 24/7 call centres. 
Measures:
Quality
  • Alerting the risk of unattended falls, dehydration, malnutrition and hypothermia;
  • Continuous reliable operation
  • Avoidance of false alerts
  • Identifying unusual activity that may indicate need for medical intervention, eg for UTIs or TIAs.
 
Safety
  • Responding to alerts in time to minimise poor health outcomes;
  • Reduction in re-admissions.
 
Cost
The cost of deploying a portable K-Socket is less than £500 per year.  If this saves an average of one excess bed day per month, then the notional return on investment will more than 500%. 
 
People
The target service users are older people awaiting discharge from hospital who:
  • Need initial support from reablement teams;
  • Live independently and do not normally have daily visitors;
  • Can respond to phone calls;
Responders to alerts may be family members, carers or 24/7 response centres.
 
Ethics
Service users must give informed consent for data sharing with approved people such as practitioners, domiciliary cares and family members.
Adoption target:
West Midlands has a population of 5 million.  Engaging 1000 suitable service users per year is a reasonable target.  100 portable K-Sockets is a minimum viability level.  If successful, then growth to 10,000 service users is practical.   
Read more
Hide details
Leonard Anderson 10/10/2018 - 09:10 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
ISL has recently developed a Clinical Trial platform that could be used for collaboration by multiple institutions including NHS/Academia/Pharma/Industry.  Shared protocols, intelligent workflows and secure data management underpin the solution.
Overview of Innovation:
Ensuring your data is accurate, your samples are viable and your results are verifiable are essential when managing clinical trials and carrying out research.

Achiever Medical provides your laboratory with the functionality to manage data quality and integrity, an audit trail to help you assess the quality of your samples and a workflow tool to help map your processes into the solution, including managing the approvals process.

  • Clinical trial functionality to allow easy adoption and customisation for launching and building up clinical trial datasets
  • Manage cohorts, studies, samples, visits and results within a single system that can be shared amongst all collaborating parties
  • One system across multiple institutes, pharma, industry and academia
  • Management reporting cross centre
  • Create and deliver trials quickly with customised data requirements
  • Enforce trial protocols to promote quality and single approach
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
  • Rapid rollout of system to support data capture of clinical trials
  • Modify processes and protocols per clinical trial with minimal recourse to IT
  • Share data regionally/nationally across trials
  • Role based permissions to protect data
  • Single system to administer
  • Adapt processes and protocols for trials quickly
Assess Sample Viability
Ensuring you are carrying out research on viable samples is essential when validating any results.  Achiever provides a comprehensive audit trail against each sample including complete details of storage location history (with a temperature audit),  sample check out history (when, by whom, how long and for what purpose) and sample processing history (with sample collection date/time, processed date/time).  A complete sample family history is also available for managing aliquots with related samples (including parent) accessible with a single click.
 
Maintaining Confidentiality
Confidentiality is not only critical when handling patient information but is also a legal requirement.  Achiever offers flexible, secure data protection options to restrict access to identifiable and sensitive information to authorised users only.  Data encryption routines encrypt data at source whilst data security filters only allow authorised users access to selected information within the system.
 
Managing Studies and Workloads
Define studies within the Achiever system and link team members along with their relevant roles.  Generate activities to create and manage workloads with a graphical calendar available to view team schedules.  Monitor and track equipment and consumables used. Capture analyses and results along with any associated documentation and images.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
  • Make clinical trials available quickly to patients within the WM region
  • Ease of reporting to present efficacy of trial within the region
  • Show proactivity of centres and success in recruiting potential volunteers for trial
Current and planned activity: 
The functionality is being rolled out within a Health Trust in the East of England.  The company now wishes to find a national / regional opportunity that would benefit from a single system to promote trials.
What is the intellectual property status of your innovation?:
Released.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Co-Authors:
Read more
Hide details
Sandie Shokar 30/08/2018 - 16:55 Publish 3 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Cera is a multi-award winning, technology-enabled homecare provider. Our technology allows us to respond and deliver tailored care within hours of an enquiry, while empowering our care-workers to deliver the highest standards of care.
 
Overview of Innovation:
Cera is a digital disruptor of the home care space, with in-house and proprietary technology. We have created a platform able to i) create digital care reports whereby during a carer visit, carers log information on their smartphone using our platform, with health and behaviour data on the user, which allows for metrics to be monitored and better care to be delivered – this data is also accessible to family members and healthcare professionals permitting much better connected services; ii) use of artificial intelligence based on the data collected by carers, to predict if users are going to experience health deteriorations such as their blood pressure worsening or the onset of a urine infection, based on subtle signals that carers may have logged – this allows us to escalate a service user’s care should they be at high risk of deterioration, or contact their doctor more proactively, potentially preventing adverse health events or the need to go to hospital; iii) use of an artificial intelligence chatbot – Martha – that provides decision support to carers based on questions they ask. The chatbot aims to transfer some of the knowledge and experience which established carers possess to carers with less experience; by doing this, we aim to make care more consistent.

Cera has provided hundreds of thousands of care hours with a 95% satisfaction rating, and is growing at an average of 25% a month. It has received over £13 million of funding from investors such as Kairos Ventures, Kima Ventures, David Buttress (former CEO of JustEat), Paul Wilmott (leads digital globally for McKinsey), Charles Songhurst (former Global Head of M&A at Microsoft) and Peter Sands (former Chairman of Davos). It has been recognised by the Government's Cabinet Office as a role model for innovative businesses partnering with the public sector, and Sir Nick Clegg recently joined the company. Cera has received a number of awards including the Most Outstanding Digital Health Innovation of the Year, the LaingBuisson Dementia Care Award, the Best London Home Care Company at the Social Care Awards 2018.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
We are the pioneer of innovative care delivery and have been widely recognised as the UK’s leader in transforming the sector. So far we have delivered hundreds of thousands of care sessions with a 95% satisfaction rating. Crucially, we are often able to start care within 24 hours when requested; this is markedly faster than other companies who take 3-4 weeks, and means that healthy people do not need to stay in hospital waiting for their care to be arranged.
We are developing a Artificial Intelligence platform that utilises data collected by carers to predict if users are going to experience health deteriorations, such as their blood pressure worsening or the onset of a urine infection. This allows us to escalate a user’s care should they be at high risk of deterioration, or contact their doctor more proactively, potentially preventing adverse health events. We are also developing an artificial intelligence chatbot that provides decision support to carers based on questions they ask. The chatbot aims to transfer some of the knowledge and experience which established carers possess to carers with less experience.

At present, clinical doctors are not involved in the active review of our clients’ data. However, there are several members of our clinical care team that review reports from each care visit through our digital care platform. Furthermore, using our digital care platform - where data is stored and viewable - it is possible for us to allow GPs and hospital doctors to access the information relating to their own clients. This would be after authenticating themselves on our platform and be possible through our portal website. We are exploring partnerships with Clinical Commissioning Groups which would allow these data sharing partnerships to be made possible.  ​
 
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
We are offering a better experience for our carers, who are offered flexible working and are empowered using technology, translating to an annual carer retention rate of over 90%. We achieve that by paying them up to 50% more than industry average, and supporting their learning via a combination of in-class and online teaching. Our e-learning platform, Learning Pool, has been very successful in engaging our carers to further their knowledge, improving the overall standards of care we provide.  

The care workers are periodically in touch with family members and are certainly aware of important care-related matters through the family members before they begin care. Care workers and family members always have the option to contact each other immediately through Cera Care at any time. Family members can access the visit reports completed by care workers through our portal as soon as they are completed - we believe this gives them a level of transparency that is simply not possible without a digitised solution. We have a comprehensive and clear consent process which all clients must sign before we deliver any care. The scope of this consent covers data capture by care workers, data storage on our platform and processing such as this for the purpose of improving patient care.
 
Our machine learning algorithm is also a work in progress - currently in prototype form. It uses data from the client’s care plan (past medical history, medication, important disabilities, care schedule) and visit reports captured by visiting care workers (mood, nutrition, hydration, activity level, sleep, bowel movements) to attempt to predict when clients are at high risk of experiencing a deterioration in their health. Currently it has an AUC ROC of 0.72. As we collect more data, we will continue to improve its performance. Since we have not operationalised this prototype, we do not require ethics approval and it is not considered a medical device because it does not offer medical diagnostic capability nor does it actively conduct treatment. If we decided to use it to inform our care workers’ practices - we can register it as a Class I device.
Current and planned activity: 
In 2018 we have delivered NHS CCG funded care with the following CCGs: Lambeth, Tower Hamlets, Haringey, Enfield, and previously had partnered with CCGs including Brent, Harrow and Hillingdon, and East London Foundation Trust, in addition to marketing in NHS hospitals including: Central Middlesex, West Middlesex, Northwick Park, Royal Marsden, Whittington and Barnet & Chase Farm and a Marketing Agreement with BMI hospitals across London. NHS 111 is exploring a collaboration with Cera. One potential outcome of this would be to permit the integration of data records from Cera into the 111 service
What is the intellectual property status of your innovation?:
We own IP for our Digital Care Platform and algorithm
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
3
Read more
Hide details
Sara Sliwinska 09/07/2018 - 16:00 Publish 2 comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Clinical decision making improved via proactive digital remote monitoring. Together driving cost efficiencies, improving patient outcomes & avoiding hospital admissions. (CE Class 1a: data server sits within HSNC:  proven ¯ 67% admissions: scalable)
Overview of Innovation:
CliniTouch Vie is a digital health solution that reduces unnecessary hospital admissions.
 
CliniTouch Vie is a locked-down tablet with integrated 3G for intensive monitoring, education & empowerment with integrated direct messaging & video support.  Dynamic care plans & evidence-based algorithms enable automatic triage for healthcare teams.  Fast & simple to implement for the most at-risk patients. 
 
Launched in 2016, system is CE marked & MHRA approved. An evidence based digital health platform that clinically supports patients to better manage their condition. It has the flexibility to be adapted for data analytics & clinical decision-making support in chronic disease management (eg COPD, heart failure & diabetes), frailty & assisted discharge programmes for ambulant & non-ambulant patients
 
Clinical & economic evidence has been generated from trials with 300 respiratory patients [Ghosh et al, 2016, https://doi.org/10.12968/bjhc.2016.22.3.123]. Our evidence based digital solution increases patient access to care & promotes greater clinician-patient collaboration for the 15million people with LTCs. It drives timely, proactive intervention, minimising need for more acute costly care enabling sustainable long-term outcomes success
 
USPs:
Evidence based: Study published in the British Journal of HC Management showed 67% reduction in unscheduled COPD admissions & saving of £2,278 per patient pa. (NB: programme continues to deliver same level of savings)
 
Patient-centred: Personalisation of goals, metrics & parameters makes system truly patient centred providing real-time remote monitoring closer to home to improve patient experience & outcomes whilst generating savings
 
Secure & integrated: Data server sits within HSNC enabling it to push-pull data securely between healthcare provider & service users. Includes bespoke integrated secure video-conferencing platform with end-to-end encryption, allowing remote monitoring of medical conditions, improving quality of life & avoiding unnecessary admissions
 
Flexible Modular Architecture: Enables clinically validated question sets re: symptoms, to be easily tailored to specific therapy areas for qualitative data collection
 
Tiered Service: no upfront costs to NHS on PAYG basis:
- Digital platform integrated into existing healthcare pathways
- Light touch triage service informing local health teams of urgent priority patients for interventions
- Fully-Managed digital platform and nurse-led service providing triage & interventions
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
CliniTouch Vie has proven benefits and can be scaled up easily across the wider regions:
  • improved patient outcomes:
  • 67% reduction in COPD emergency admissions;
  • 13% improvement in CAT score
  • 97% of patients using CliniTouch Vie will further reduce distress and discomfort from conditions exacerbations
These were supported by:
  • improved access to healthcare: 24/7 access to healthcare, average 110 interventions per patient per annum (500% increase)
  • targeted and personalised health interventions: 7,250 personalised clinical interventions (data from 66 patients over 12 months)
  • data analytics: real-time clinical dashboards for clinical teams to prioritise patient needs; prioritised only 38% of patient clinical recordings required intervention within a 24-hour period
 

 
Patients are educated and supported to interpret the data to gain an improved understanding of their health status.CliniTouch Vie:
  1. Educates patients: supporting people to make health life choices through improving the understanding of their disease and self-management skills
  2. Enhances care for patients with chronic conditions: informing and engaging patients as part of NHS prevention agenda and creating a patient-provider collaboration
  3. Provides data analytics: making more targeted and personalised health interventions, by using disease specific algorithms to differentiate when one patient’s history or recent environmental exposures indicates a higher likelihood of flare up than another
  4. Improves patient safety: providing real time clinical and well-being data to identify early warning signs of health deterioration, medication adherence and self-management education
  5. Reduces hospital activity: providing real time management of high risk patients to prevent admissions
  6. Supports early discharge: providing hospital level diagnostics and monitoring in the home, enabling early discharge and can be used for remote clinical support post-surgery or in care-home settings
  7. Delivers workload efficiencies: supporting better patient self-management, reducing need for direct interventions and enabling staff to focus on priority patient care
  8. Offers locality wide cost savings: reduced demand leads to reduced NHS activity
 
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
The West Midlands priorities that CliniTouch Vie can address are:
  • P2: Long Term Conditions: whole system, person centred approach
  • P4: Wellness, healthy aging and prevention of illness
  • P8: Digital Health
 
Our vision is for CliniTouch Vie to contribute towards and support the West Midlands wider vision to develop a worldwide reputation for delivering healthcare through digital technologies, proven to deliver sustainable improved outcomes and create wealth.  We have already demonstrated that it can deliver on all fronts with high risk COPD patients and is being adopted for Heart Failure, Diabetes, Cancer and Frailty pathways.  With an ageing population, often with co-morbidities, it can be used to support a more patient-centric approach to health care services in the region.
 
CliniTouch Vie supports health and wealth benefits as is a flexible, real-time remote monitoring solution, facilitating earlier discharge, prevent readmissions, reduce risk of future exacerbations and improve self-management through our inbuilt education resources.  CliniTouch Vie delivers a proactive approach to tackling symptoms, preventing exacerbations and slowing health deterioration, resulting in reduced NHS costs.  The system has an extensive data collection of medical, lifestyle, biometric and daily activity.
 
Targeting patients who are at risk or have multiple hospital admissions could significantly reduce the NHS costs to the region as well as freeing up clinic and nurse time to manage a wider caseload more efficiently. With a more collaborative, integrated, patient centred approach, utilising proven remote digital health, the West Midlands could see a potential reduction in admissions by 60%+.
 
CliniTouch Vie is a locked-down tablet, with integrated 3G for intensive monitoring, education and empowerment with integrated direct messaging and video support.  Our dynamic care plans and evidence-based algorithms enable automatic triage for healthcare teams. 
 
The tablet comes in an easy to carry case with the peripherals and can be handed to the patient at home, in clinic or upon discharge and is linked directly to the clinician web-based management portal.  Data within CliniTouch Vie tablet is stored securely within the cloud and hosted on the N3.  This makes CliniTouch Vie easy to scale due to its low technology and estates requirement, whilst delivering a high quality clinical service.
Current and planned activity: 
Current:
Spirit Digital is part of Spirit Health Group and can provide one of the most comprehensive range of solutions to support patients of all ages, IT capabilities & levels of disease severity across a wide range of conditions e.g. respiratory, cardiovascular, diabetes, cancer, frailty.
 
Spirit is establishing research collaborations with academic institutions around evidence generation for AI and machine learning. This includes collaboration on a bid to the European Space Agency to further develop the technology using satellite data.

Planned:
Spirit Digital seeks WMAHSN support ta assist with introductions and marketing of CliniTouch Vie to local CCGs. 
 
Our planned NHS engagement activity programme for the next 12 months will be through a variety of channels:
  • Direct engagement with CCGs and community Trusts
  • Application to Digital Accelerator programme
  • Case study development & sharing
  • Presentations at national conferences
  • Creating user (clinicians & patients) video footage to share with CCGs
What is the intellectual property status of your innovation?:
We hold the IP for the technology and digital health algorithms.  We collaborate with Midlands based businesses, healthcare providers and universities and retain all IP for products and services.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Read more
Hide details
Emma-Jane Roberts 21/06/2018 - 12:25 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
QxMD is a company dedicated to creating point-of-care applications created by for healthcare professionals, with a global community of 1.9 million clinicians, medical students, scientists and researchers and are free to download and use at any time. 
Overview of Innovation:
Healthcare professionals need to stay up to date on the latest medical research and topic reviews to provide optimal care. Unfortunately, the process of content discovery is broken with research artificially compartmentalised by publishers and hidden behind countless institutional paywalls.

At QxMD, we believe that knowledge translation– the process by which new knowledge is incorporated into clinical practice – is an important and unsolved challenge for our health care system. Read uses smart algorithms to ensure that each and every user has a dedicated newsfeed of research that applies to their practice. 
With Read, Institutional Edition, organisations can seamlessly integrate their existing journal subscriptions and existing proxy service to provide a platform for their clinical staff to access content which matters to their individual practices. It is built with features designed to improve patient care and reduce costs. 

The Promoted Research feature is used by institutions who want to disseminate research that impacts areas of care the most within their organisation. For example, a Hospital with high rates of Sepsis can use this tool to promote guidelines that reduce Sepsis cases with higher guarantees their clinical staff will discover the research and apply it to the next patient. 

Librarians and Knowledge Managers can take advantage of smart analytics to understand which journal subscriptions are performing the best and worst and also which journals are most popular, which they don't subscribe to.

NHS Trusts are already adopting QxMD, with over 100,000 users in the UK alone. 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
  • Better educatad and up-to-date staff, specific to their practice
  • Cost saving on journal subscription costs
  • Improved patient care
  • Challenges identified and tackled via the Promoted Research feature
  • Easy to discover and access research from any smart device
  • Links with OpenAthens for instant access to subscribed content. 
Initial Review Rating
2.60 (1 ratings)
Benefit to WM population:
  • Better educated healthcare professionals who can identify the latest research and apply it to patient care
  • Less chances of mis/under diagnosis, readmission or even death
  • Improved quality of care
Current and planned activity: 
  • Existing NHS Trust clients, including the largest Mental Health Trust in the UK
  • Continue to grow our userbase, which is already at 100,000 UK users, with the support of Trusts and other stakeholders. 
What is the intellectual property status of your innovation?:
  • We have designed and developed the platform entirely in-house. No white-labelling. A completely unique tool built by Healthcare Professionals for Healthcare Professionals. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Jimmy Connoley 19/06/2018 - 12:56 Publish 2 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Currently, a GP refers Obstructive Sleep Apnoea patients to an NHS Specialised Sleep Centre. Averaging 24 wks & 3-5 hospital visits before the Patient starts treatment.
Now, a GP with SOMNOtouch can receive results in 48-72Hours (3days vs. 6Mths)
Overview of Innovation:
Currently
The vast majority of patients with Obstructive Sleep Apnoea (OSA) are referred by their GP to a Specialised Sleep Centre at an NHS Hospital with a Average waiting time 12 Weeks


Patients are initially seen by a Consultant or a Sleep Physiologist who would prescribe a Diagnostic Study to be performed either in hospital or at the patient’s home. Average waiting time 12 Weeks
The patient returns to have the sleep study done or to collect the monitor and then returns the device the next day. After a further waiting time of upto 6 Weeks the patient visits the hospital again to obtain the results of the sleep study and if Positive, to discuss treatment.
A letter is sent to the GP informing them of the results and if agreed, a prescription is issued by the GP for the recommended therapy this may also take an average of 6 Weeks to arrive.
 This is prior to any treatment being administered such as a CPAP where if used they attend annually to check on compliance and progress.
 
This 6 month process is dramatically reduced by the S-Med Service to just a few days before an intervention can be delivered.


Now
The GP fits SOMNOtouch, a Combined OSA/Hypertension Monitoring Device to the patient, after 24 hours they return to the GP practice where the device is removed and the GP uploads the data from the device to a secure NHS Digital Cloud Server.
SOMNOtouch NIBP - Five devices in One
Video link: http://www.s-med.co.uk/Products#nav-product-86
 
S-Med Ltd’s Qualified and Registered Physiologists interprets the study and provides a recommendation for further treatment or investigation within 24 to 48 hours to the GP surgery. (All analysis and interpretations are supervised by a senior Consultant).
 
The report is sent to the GP who would then provide a prescription for the relevant therapy to be provided.
 
Thus within 48 to 72 hours a patient can be treated or directed for additional investigations or treatment before their condition deteriorates.

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Faster response times and time to providing treatment from an average time from referral to treatment of 6 months (24 weeks) down to 4 to 5 days (1 week). With the added benefit if there are more critical underlying conditions then these may be picked up and dealt with quickly
 
Reduction in costs of patients being referred to NHS sleep centres thus less calls and pressure on such specialist clinics e.g.:
 
Reimbursement Tariffs for OSA and Hypertension
Current reimbursement guidelines from the Department of Health are:
  • For Ambulatory Sleep Diagnostic Study: £391.00
  • For 24-Hour NIBP Study: £268.00 (UCL NHS Foundation Trust, there is no NHS tariff)
  • For 24-Hour ECG Study: Recording - £268.00 plus Analysis £215.00 (UCL NHS Foundation Trust, there is no NHS tariff)
 
Cost Savings Calculation
Assuming the following:
  1. Adult Population of the England is Approx. 45 million
  2. BLF figure show approx. 10% of population suffers from OSA = 4.5 million
  3. DH figures show that approx. 30% of adult population has Hypertension = 13.5 million
  4. Public Health England shows that 1.3 million people have Atrial Fibrillation
 
The cost of referring 1% of the above population to hospital annually, will cost approximately:
  1. OSA – 45,000 £32 million per year.
  2. Hypertension – 135,000 £79 million per year
  3. AF – 13,000 £10.5 million per year
 
Total cost of £121.5 million
Cost of S-Med Service - £38.6 million
Savings to NHS = £83 million per year.
 
Aside from OSA, this equipment can be used for chronic heart conditions studies as well as more longitudinal studies adding a wealth of data for clinicians to inform them of patient’s conditions at work, rest and play without the equipment being intrusive and disturbing as current cuff based systems thereby removing the abnormal results they can provide. Thus, this equipment may also be of benefit to clinical trial units or during treatment to monitor the physiological effects experienced by patients undergoing a drug or other clinical interventions. 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
In addition to patients getting a faster diagnosis, it will reduce the burdens on NHS Trusts not only from the reduction on 1st line referrals to hospitals, but from patients conditions deteriorating, or suffering economic or social problems waiting 6 months for a diagnosis and treatment to be considered.

North West Innovation Agency (AHSN) will be conducting a pilot which will monitor 75 patients via a number of GP’s Practices. Results should be available by the End of February 2018.
As a West Midlands based company we would welcome an opportunity to work with NHS Trusts and CCG’s within the region to help us grow this service within the UK for the NHS and to increase our team to service and facilitate such requirements.  
Current and planned activity: 
Current NHS engagement
  • Embarking on a NIA application with North West Innovation Agency
  • Submitted an application into the ITP based on experience and adoption within the NWIA area.
  • Considering a NIHR project following a meeting at AHSN meeting - Speaking with West Midlands NIHR/CRN
Requested NHS engagement
  • Procurement / Adoption of: -  Would welcome assistance to gain greater Adoption by Trusts and CCGs within the West Midlands
     
  • Evaluation / Validation / Clinical Trial – Interested in trials for use of our ambulatory equipment (SOMNOtouch) within new clinical areas to show its versatility and extend its clinical use to provide validated evidence within in these new areas.
     
  • Project Assistance S-Med is interested in locating potential clinical / academic collaborators to engage in their current work and to explore other clinical applications of their technology.
What is the intellectual property status of your innovation?:
Device IP held by SOMNOmedics Germany. Clinical diagnostic and reporting service is owned by S-Med Ltd.
Reg. CE0494
We have obtained IGSoC Level 2 (ODS Code: 8JP12)
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
3
Read more
Hide details
Selwyn Sher 03/10/2017 - 13:27 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Sometimes it’s hard to prove impact. Risk Tracker helps organisations providing preventative services to record their work & demonstrate success. Provided free for anyone to use (under open license) Risk Tracker is for use on desktop & mobile devices
Overview of Innovation:
Risk Tracker is a powerful tool for managing clients and demonstrating outcomes. Designed to record information without getting in the way of the service you provide, it requires collection of a minimal amount of information from clients, but provides you with the flexibility to customise.
 
One of the key challenges for organisations who provide preventative services is connecting your clients’ progress with the complex range of National Outcome Frameworks. Inside Outcomes continuously maintains the policy environment to ensure that your reports will always reflect the most recent National Outcome Frameworks and, as the Frameworks evolve, we keep you up to date with the impact this will have on your day-to-day operation.
 
We have collated a database of issues that are common to preventative services. The system has been designed to support care navigation services by providing a quick tool to record client notes, measure outcomes and store files.
 
The Inside Outcomes Risk Tracker tool helps organisations to:
  • Record the common issues that clients present to services
  • Measure changes in those issues over time
  • Demonstrate the impact organisations have had in an evidence based way
  • Measure the impact organisations have had against National Outcome Frameworks
We have created a series of custom Risk Maps that reflect the issues clients commonly report, and aligned them with the public health life course. These Risk Maps cover diverse issues such as financial planning, housing and wellbeing, because we know the complexity of individual circumstances has an impact on your ability to provide services.

Our Risk Maps cover: We are also able to tailor risk maps to reflect service specific needs such as:-  
We also provide the facility to run anonymised open data reports that highlight social need in a particular area. Because we used a standardised format for recording the issues that people present we can aggregate data across multiple agencies to create a powerful, live commissioning tool.
 
We provide Risk Tracker free for anyone to use. We provide it under an open license so that you can run it in any way you want or even adapt the code for your own uses. You can access the code repository on our Github site. You can access the Risk Tracker manual here.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Health is influenced by a range of social, environmental and economic factors which are beyond the remit of the health sector.
 
Health services, social care and housing are all focused on delivering better outcomes at lower cost to public purse and finding ways of improving the effectiveness and better understanding the value of preventative services.
 
Risk Tracker measures the impact of organisations against national outcome frameworks, supporting them to translate the things they do into the outcomes that commissioning bodies are measured against.
 
Commissioners need to identify what services are required to deliver improvements in the prevention, diagnosis and treatment of physical and mental illness in their local population, Risk Tracker provides important data to identify top priorities and opportunities for transformation.
 
It helps commissioners to identify sub groups within their population and consider service requirements across the system, creating the person-centred services patients want and need.
 
Risk Tracker is a useful tool for analysing population data and identifying those who would gain most from the services and interventions being considered, commissioners then use this information to plan, deliver and monitor services for their local population.
 
When contracting for services, commissioners are looking for positive social outcomes, which have a lasting impact with benefits for patients that can be clearly demonstrated.
 
With Risk Tracker, information is used to improve services and influence commissioning decisions. Through recording client issues in a common format Risk Tracker allows the outcomes from disparate services to be compared and contrasted. For example, the cross over in issues that the clients present to substance misuse services, mental health services and housing associations mean that data can be aggregated together.

As all data is stored in a single, secure, compartmentalised system we can create aggregated, anonymised maps of social need. The live data that can be produced records social need and is an essential tool in commissioning services against evidenced social need.
 
Investing in prevention and better health outcomes can be part of the solution to the challenges of increasing levels of need along with shrinking budgets. Effective preventative interventions can reduce health and social care costs and the need for welfare benefits. Better health can also enhance resilience, employment and social outcomes.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Risk Tracker helps commissioners to plan services which meet national standards and local ambitions, by combining knowledge of existing service performance and population needs.
 
Commissioners traditionally do not have access to live local data. Having the ability to extract accurate data on health and wellbeing needs for a particular area supports a flexible approach to commissioning against need.
 
The methodology that underpins our system encourages services to carry out a whole person assessment.  This means exploring the range of issues that might be present in an individual’s life. Through identifying a range of interdependent issues, services can integrate how they work around an individual and improve their outcomes.
 
An important component of planning for transformation is recognising where services may
need to be decommissioned. Risk Tracker can help to identify where less effective approaches to service delivery are to be found. With a good understanding of how a service is currently operating commissioners can identify potential opportunities for innovation and improvement.
 
With Risk Tracker commissioners can develop service specifications that focus on paying for services which produce improved outcomes for their patients, rather than reimbursing providers for activity.
 
Risk Tracker will provide commissioners with the information they need to develop a vision of future service provision that will improve the health & wellbeing of individuals and communities in the West Midlands.
 
We provide Risk Tracker free for anyone to use. We provide it under an open license so that you can run it in any way you want or even adapt the code for your own uses. You can access the code repository on our Github site. You can access the Risk Tracker manual here.
Current and planned activity: 
Risk Tracker is a cloud based system & is constantly going through development as services identify new functions. We are currently exploring developing risk maps to support refugees & asylum seekers, people with disabilities, carers & suicide prevention.

Our next significant software release will incorporate individual access to records & the ability for clients to move their records from one agency to another. We believe that a person-centred approach to improving health & wellbeing requires the ability for individuals to manage their own records.
 
We would like WMAHSN to help to scale up Risk Tracker across the WM region. It is provided free of charge under an open license & users can run it in any way they want, even adapt the code for their own uses. By using WMAHSN’s network to promote this opportunity, WM commissioners can develop service specifications that focus on paying for services which produce improved outcomes for patients rather than reimbursing providers for activity.
What is the intellectual property status of your innovation?:
Inside Outcomes own the full IP for the product but release it for use under an open source license. 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
The Risk Tracker system has been built to be delpoyed at scale. The system can manage an unlimited number of organisations, and projects within organisations. The platform the system is built on is designed to dynamically utilise server capacity in line with the number of organsations using it. 
Measures:
The prinicple outcome we are aiming for is to be able to produce live data on social need for an area. 
Adoption target:
We are looking at opportunities to support neighbourhood working in line with strategic objectives of the West Midlands Combined Authority. The Risk Tracker system has been designed to set a basis for metrics in disaparate organisations and be used to integrate services using a common format of data collection. 
Read more
Hide details
Darren Wright 05/09/2017 - 16:35 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Our expert people and advanced health analytics reveal insights from complex data that enable health & care professionals working across the West Midlands to make better decisions for the patients and populations they serve.
Overview of Innovation:
Sollis and the world-renowned Johns Hopkins University have collaborated to produce a population health analytics platform that helps health & care professionals transform services for patients and populations.
 
Sollis Clarity and The Johns Hopkins  ACG ®System is a person-focused case-mix system that captures the multi-dimensional nature of an individual’s health. It considers the total disease experience of each patient, including the implications of co-occurring disease, encouraging a holistic view of the patient rather than the management of specific diseases or episodes.
 
Sollis Clarity supports:
  • Case Finding - Patient level risk stratification
  • Resource Management - Case-mix risk adjustment and benchmarking
  • Population Health Needs Assessment - Population level risk stratification
  • Fair Shares Budgeting - Capitated budget setting
 
Sollis Clarity delivers robust business analytics and data management to identify and analyse populations across the continuum of care to help health & care providers and commissioners get a precise understanding of patterns of mult-morbidity across populations and its relationship to utilisation, costs and outcomes.
 
Sollis Clarity delivers insights into the morbidity patterns of different populations, supporting population health management, service transformation, integrated care and, ultimately, better outcomes for patients.
 
Sollis Clarity goes beyond patient level risk stratification. Risk stratification at a population level helps the health economy — providers and commissioners — analyse and minimise the progression of diseases and the exacerbation of co-morbidities. When combined with the ACG System it is a comprehensive family of measurement tools designed to help explain and predict how healthcare resources are delivered and consumed.
 
Sollis Clarity provides the evidence base to support:
  • Planning and service re-design
  • Clinical decision making
  • Outcomes-based commissioning
  • Risk stratification and predictive modelling
  • Population profiling / segmentation
  • Case-mix adjusted benchmarking
  • Integrated multi-disciplinary care
To view Sollis - Nigel's Story - click here.
To view UK Healthcare data analytics for NHS CCGs - click here.
To view The Proactive Care at Brighton & Hove - click here.
To view Population Profiling at NHS Slough CCG - click here.
To view Using Data to Gain Greater Insight - click here.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wealth creation / Digital health
Benefit to NHS:
Population health analytics delivers an evidence base (insights from data) that supports large scale health & care service transformation. It is an essential component of any Population Health Management strategy and as such underpins the journey to a fully fledged Accountable Care System (ACS).

The Sollis Clarity health analytics platform is a modular system with mix-and-match components to help you achieve your healthcare analysis and commissioning/budgeting requirements.
 
Population health management helps Health & Care stakeholders identify and quantify the drivers and outcomes for addressing the needs of local populations.
 
Led by directors with decades of NHS experience, Sollis analytics software and professional services have been used to analyse data on nearly half the population of England. We believe patient-centred care strategies based on the needs of local populations provide the key to better population health management.
 
Sollis Clarity is helping several CCGs in the UK to implement new reporting and service planning initiatives.  To view examples of ‘Service Transformation: Stories from the CCG Frontline’ summarising how CCGs are using the insights provided by Clarity Patients and ACG® System analysis for service planning and transformation – click here.
 
The Sollis Clarity health analytics platform has two distinct but complementary solutions — Clarity Patients and Clarity Finance — address population health management and financial analysis respectively.
 
Clarity Patients, combined with the Johns Hopkins ACG® System, provides a comprehensive family of measurement tools that helps explain how healthcare resources are delivered and consumed. It supports new commissioning models such as Commissioning for Value, Outcomes Based Commissioning and Year‑of‑Care Commissioning. It delivers analytics that provide insights to support health & care interventions and innovation and it will help you track the success — or otherwise — of those innovations over time.
 
Clarity Finance provides contract management and activity costing with multiple tariffs, giving you business critical evidence on which to base commissioning decisions. It enables you to store and compare different versions of cost and volume type tariffs as well as non-activity tariffs, such as year of care or outcome based currencies, to give you insights on the most effective commissioning decisions.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Knowledge of the risk profile of the region’s population (based around a population segmentation approach) will help Health & Care stakeholders across the West Midlands commission and deliver appropriate preventative services that will drive positive health outcomes for the 'at need' populations of the West Midlands. 

Through the innovative use of information technology to identify patients most in need of an intervention (impactable patient cohorts) Sollis Clarity helps to identify patients who could most benefit from earlier, better informed health care interventions.
 
The Sollis population health analytics platform allows the patient population to be risk assessed to provide timely, evidential data to all members of a Multi-Disciplinary Team (MDT), to include clinicians but not limnited to them. This enables MDT members to provide focused levels of care to specific groups of patients, reducing the risk of a patient’s condition worsening due to it being identified early so assisting MDT members in identifying and improving the care of at-risk patients.
 
Much can be achieved through the acquisition of primary care, secondary care, community care, mental health, prescribing and social care data. It can provide a rich understanding of how healthcare resources are delivered and consumed and by whom. Such analysis can aid an understanding of whether scarce resources are being deployed to those population groups in greatest need.
 
It is important that any population health analysis should focus not on single disease conditions, but on the burden of multi-morbidity observable in a local population.  Population health programmes that have the best chance of success will be those that demonstrate an understanding of the importance of multi-morbidity and its impact on the local health and care economy.
 
Using data to identify early healthcare interventions can provide significant benefits to patients, particularly those with long-term conditions. Providing the functionality to make real time decisions based on clinical evidence will improve outcomes for patients.
 
Sollis exist to help our customers deliver better patient outcomes, better patient experiences at an affordable cost and are wholly focused on the delivery of insights that will help deliver a sustainable and transformed health and care system in the West Midlands.
Current and planned activity: 
We are currently providing analytics support to thirty (30) plus Clinical Commissioning Groups (CCGs) nationally as well as nine hundred (900) plus GP practices and a number of NHS Vanguards, principally Multispecialty Community Providers (MCPs).

We would like to engage with health and care professionals involved in the development and evaluation of New Care Models throughout the West Midlands who want to use evidence based data to understand patterns of multi-morbidity and its relationship to utilisation, costs and outcomes. We are particularly interested in engaging with Sustainability & Transformation Paernerships (STPs) and emerging Accountable Care Systems (ACS).
What is the intellectual property status of your innovation?:
Sollis owns all Intellectual Property (IP) for the following software applications:
  • Sollis Clarity (Population Analytics Platform)
  • Sollis Clarity Patients
  • Sollis Clarity Finance
 Johns Hopkins Health Care (JHHC) owns all Intellectual Property (IP) for the following software:
  • ACG® System
 Also:
  • ISO9001
  • IG Toolkit Certified
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
2
Read more
Hide details
Nigel Slone 21/08/2017 - 11:53 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
InterCare® enables digital health monitoring, self-care support, video consultations and social messaging - securely connecting patients with clinicians, care providers and family.
Overview of Innovation:
InterCare® is designed to make digital healthcare more accessible – with intuitive healthcare technology for elderly people, vulnerable adults, as well as patients who are more tech-savvy.

 
InterCare® takes a new approach to telehealth – integrating vital signs monitoring, self-care support, video calling and secure messaging in an accessible format. 

The intuitive digital platform and easy-to-use controls are designed to make healthcare technology accessible to all – including elderly people and vulnerable adults.

This versatile solution keeps patients in touch with everyone in their health and wellbeing network – clinicians, carers and family.  Proven in an NHS setting to reduce home visits and emergency hospital admissions, whilst significantly improving patients' health and wellbeing. 

Patients access the platform via InterCare® TV or InterCare® Mobile. A patient's own television can be InterCare®-enabled with a HDMI stick, webcam and user-friendly, large-scale keyboard controls.  This brings accessible technology to a broad range of patients, including the elderly, vulnerable, those who need support with chronic conditions and rehabilitation.

Patients can digitally track vital signs, such as blood pressure and oxygen levels – with alerts when these fall outside pre-set parameters, directing patients to their self-care action plan and ‘virtual’ consultations with their healthcare team when needed.  Empowering long-term-condition patients to take a proactive role in the management of health conditions, providing added reassurance, improving outcomes and reducing NHS costs.

InterCare® digitally connects patients with their professional and personal support network via secure messaging and video calls.

Clinicians and other health and care professionals can securely access the system via InterCare® Web or the InterCare® Mobile app. Family members can connect via InterCare® Web.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
InterCare® is a digital healthcare technology that enables NHS professionals, carers and family to be connected to a central user, in their home or assisted living facility.

InterCare® delivers health-data monitoring and alerts, video consultations, multi-disciplinary team messaging, self-care video content, health questionnaires and more, through a TV or mobile interface.  InterCare® TV makes digital healthcare technology accessible to a broad range of patients, including the elderly, vulnerable and others who need support with chronic long-term conditions. 

The NHS benefits from connected, efficient care of long-term-condition patients, in their own homes.  Empowered patients take a proactive role in the management of their health conditions, reducing anxiety and improving outcomes.  The resulting reduction in the numbers of home visits, appointments, A&E attendances and unplanned admissions, delivers significant savings for the NHS across some of the costliest population cohorts.

A recently completed 12-month NHS deployment, connected patients with severe COPD to their community respiratory nurses.  InterCare® TV was installed in the patient’s own houses in South Tyneside and a wide range of functionality utilised.  Wider care and family networks were also connected where appropriate and the following improvements in condition management and outcomes were reported:
  • 37% reduction in unplanned admissions
  • 33% reduction in home visits
  • 43% reduction in follow-up outpatient visits
  • 50% COPD users showed improved cat scores
  • 62% of patients with reduced anxiety scores
  • 43% of patients with reduced depression scores
  • 100% usability reported by patients
 
The cost effectiveness of the InterCare solution demonstrated by these reductions is significant, when set against the standard NHS costs for patient interventions in either community, primary or secondary care.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
Could do with advice on filling this section
Current and planned activity: 
We have launched a new website which details the use of InterCare® in an NHS environment and carries case studies.  We are seeking to hold meetings with CCGs/ACOs/STPs where an expression of interest in utilising technology to assist in the management of long term condition patients in their own homes or in assisted living environments.  We have the potential agreement in three locations to work with clinicians who see the benefit of our InterCare® solution but do not have funding available to them. We are seeking funding in order to move forward with those pilots.
What is the intellectual property status of your innovation?:
Wholly owned by Nimbus Medical.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
3
Rejection Reason:
Unable to contact innovator to clarify aspects of the submission
Read more
Hide details
Mark Pedder 04/08/2017 - 15:57 Rejected Login or Register to post comments
0
0
Votes

Recent Activities

My Diabetes My Way: A Patient Support Platform for those with Diabetes has been moved from Initial Submission to Publish 6 hours 20 min ago
IoT solutions for Integrated Health and Social Care Technology has been moved from Initial Submission to Publish 1 month 2 weeks ago
Biobanking Management Software - MbioLIMS has been moved from Initial Submission to Publish 2 months 2 weeks ago
Amplitude ​pro enterprise has been moved from Initial Submission to Publish 2 months 3 weeks ago
Sonia Hussein commented on Sensium: Early Detection of Patient Deterioration. Seamless ambulatory vital sign monitoring for the general ward population. 3 months 5 hours ago

Active Campaigns